Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

Another notable valuation metric for BMY is its P/B ratio of 6.19. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.18% ...